Evidence map›Paper›PMID 31319863›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.

Chiara Ciardiello, Alessandra Leone, Paola Lanuti, Maria S Roca, Tania Moccia, Valentina R Minciacchi, Michele Minopoli, Vincenzo Gigantino, Rossella De Cecio, Massimo Rippa and 13 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Liquid Biopsy in Endometriosis: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 3 countries.

Chiara CiardielloExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy. c.ciardiello@istitutotumori.na.it.
Alessandra LeoneExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Paola LanutiCentre on Aging Sciences and Translational Medicine (Ce.S.I.-Me.T.), University "G.d'Annunzio", Chieti-Pescara, Italy.
Maria S RocaExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Tania MocciaExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Valentina R MinciacchiGeorg-Speyer-Haus Institute for Tumor biology and Experimental Therapy, Frankfurt, Germany.
Michele MinopoliNeoplastic Progression Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.
Vincenzo GigantinoPathology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.
Rossella De CecioPathology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.
Massimo RippaInstitute of Applied Sciences and Intelligent Systems 'E. Caianiello' of CNR, Pozzuoli, Italy.
Lucia PettiInstitute of Applied Sciences and Intelligent Systems 'E. Caianiello' of CNR, Pozzuoli, Italy.
Francesca CaponeExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Carlo VitaglianoExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Maria R MiloneExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Biagio PucciExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Rita LombardiExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Federica IannelliExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Elena Di GennaroExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Francesca BruzzeseExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.
Marco MarchisioCentre on Aging Sciences and Translational Medicine (Ce.S.I.-Me.T.), University "G.d'Annunzio", Chieti-Pescara, Italy.
Maria V CarrieroNeoplastic Progression Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.
Dolores Di VizioDepartments of Surgery, Pathology & Lab Medicine, and Biochemical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alfredo BudillonExperimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy. a.budillon@istitutotumori.na.it.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITInstitute of Applied Science and Intelligent Systems · ITUniversity of Chieti-Pescara · ITCedars-Sinai Medical Center · USGeorg Speyer Haus · DE

Funding

Molecular Mechanisms of Large Oncosome-Induced Prostate Cancer Progression and MetastasisR01CA234557 · NCI · CEDARS-SINAI MEDICAL CENTER · PI DI VIZIO, DOLORES · 2019 to 2023
$2.3M
Associazione Italiana per la Ricerca sul Cancro Fellowships AIRC-FIRC for Italy 19586Ministero della Salute Institutional Ricerca Corrente funds - Project M3_6NCI NIH HHS R01 CA234557
6 · The paper itself

Abstract

backgroundMolecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as "Large Oncosomes" (LO), have been identified in highly migratory and invasive PCa cells. We recently developed and characterized the DU145R80 subline, selected from parental DU145 cells as resistant to inhibitors of mevalonate pathway. DU145R80 showed different proteomic profile compared to parental DU145 cells, along with altered cytoskeleton dynamics and a more aggressive phenotype.

methodsImmunofluorescence staining and western blotting were used to identify blebbing and EVs protein cargo. EVs, purified by gradient ultra-centrifugations, were analyzed by tunable resistive pulse sensing and multi-parametric flow cytometry approach coupled with high-resolution imaging technologies. LO functional effects were tested in vitro by adhesion and invasion assays and in vivo xenograft model in nude mice. Xenograft and patient tumor tissues were analyzed by immunohistochemistry.

resultsWe found spontaneous blebbing and increased shedding of LO from DU145R80 compared to DU145 cells. LO from DU145R80, compared to those from DU145, carried increased amounts of key-molecules involved in PCa progression including integrin alpha V (αV-integrin). By incubating DU145 cells with DU145R80-derived LO we demonstrated that αV-integrin on LO surface was functionally involved in the increased adhesion and invasion of recipient cells, via AKT. Indeed either the pre-incubation of LO with an αV-integrin blocking antibody, or a specific AKT inhibition in recipient cells are able to revert the LO-induced functional effects. Moreover, DU145R80-derived LO also increased DU145 tumor engraftment in a mice model. Finally, we identified αV-integrin positive LO-like structures in tumor xenografts as well as in PCa patient tissues. Increased αV-integrin tumor expression correlated with high Gleason score and lymph node status.

conclusionsOverall, this study is the first to demonstrate the critical role of αV-integrin positive LO in PCa aggressive features, adding new insights in biological function of these large EVs and suggesting their potential use as PCa prognostic markers.

Indexed as

AnimalsCell AdhesionCell Line, TumorEpithelial-Mesenchymal TransitionExtracellular VesiclesGene Expression Regulation, NeoplasticHumansIntegrin alphaVMaleMiceMice, NudeNeoplasm GradingNeoplasm InvasivenessNeoplasm TransplantationProstatic NeoplasmsProteomicsIntegrin alphaVProto-Oncogene Proteins c-aktAKTAlpha-V integrinExtracellular vesiclesOncosomesProstate cancer

Identifiers

PMID31319863
PMCPMC6639931
OpenAlexW2956588751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.